Oyagüez I, Casado MA, José Farfan Sedano FJ, Apezteguía Fernández C
Análisis de costes de natalizumab frente a fingolimod en el tratamiento de la esclerosis múltiple
32 jornadas de Economía de la Salud (AES). Bilbao, España. 15-18 may 2012
Sánchez-de la Rosa R, Sabater E, Casado MA, Arroyo R
Cost-effectiveness Analysis of Disease Modifiying Drugs (Interferons and Glatiramer Acetate) as first line treatments in Remitting-Relapsing Multiple Sclerosis patients
14th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Madrid, Spain 5-8 nov 2011
Sánchez-de la Rosa R, Sabater E, Casado MA
Budget impact analysis of first-line treatment for relapsing-remitting multiple sclerosis in Spain
14th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Madrid, Spain 5-8 nov 2011
Collar JM, Porta-Etessam J, Tobaruela JL, Rabes C, Casado MA
Burden of disease in moderate Alzheimer disease patients with depression in Spain (Ideal Study)
11th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Athens, Greece. 8-11 nov 2008
Kobelt G, Berg J, Lindgren P, Izquierdo G, Sánchez-Soliño O, Pérez-Miranda J, Casado MA